Get the Daily Brief
Latest Biotech News
Sequencing vendors scale: Ultima installs rise; Element teases $100 genome benchtop
Ultima Genomics said it doubled its installed base in 2025, reported a multi‑fold rise in consumables revenue and a contracted revenue backlog more than double 2025 revenue as it expands...
Redosing and regulatory ease reshape CGT strategy
Immusoft reported it achieved redosing with its ex vivo Immune System Programming (ISP) platform and advanced ISP‑001 into Phase I/IIa for MPS‑I; the company emphasized redosing’s potential to...
WGS moves toward clinical utility: HRD detection and ASO collaborations
A pan‑cancer study using whole‑genome sequencing (WGS) and an HRD classifier found homologous recombination deficiency signatures missed by other assays, detecting HRD across breast, pancreatic,...
JPM deal surge and biotech’s renewed M&A momentum
Industry briefs from the J.P. Morgan Healthcare Conference show rising M&A activity and renewed venture deployment: analysts cited a surge in fourth‑quarter biotech venture investments and $64...
AbbVie licenses PD‑1/VEGF bispecific from RemeGen: $650M upfront
AbbVie agreed an exclusive license with China’s RemeGen for RC148, a PD‑1/VEGF‑targeted bispecific antibody, paying $650 million up front and reserving up to $4.95 billion in milestones. The deal...
Illumina unveils billion‑cell atlas: AI dataset to speed drug target work
Illumina launched the Billion Cell Atlas, a perturbation‑heavy, genome‑wide dataset aimed at training AI models and validating drug targets, and said it has generated roughly 150 million cells to...
Lilly and Nvidia commit up to $1B: five‑year AI drug‑discovery lab
Eli Lilly and Nvidia announced a multiyear partnership to build an AI drug discovery lab, committing up to $1 billion over five years to compute, infrastructure and joint model development. Lilly...
Precede raises $83.5M, scales liquid biopsy platform for pharma
Precede Biosciences closed $83.5 million in Series B financing and secured a $20 million non‑dilutive credit facility to expand capacity for its blood‑based transcriptional liquid biopsy platform....
Proximity‑drug startup Proxima closes $80M seed; rebrands from VantAI
Proxima (formerly VantAI) closed an oversubscribed $80 million seed round led by DCVC and backed by Roivant and others to develop AI‑driven proximity‑modulating drugs that target protein...
FDA approves Zycubo — first therapy for Menkes disease
The U.S. Food and Drug Administration approved Zycubo (copper histidinate, CUTX‑101) as the first treatment for Menkes disease, a fatal pediatric disorder of copper absorption. Sentynl...
FDA again rebuffs Atara’s cell therapy... company calls agency reversal a 'complete reversal'
The FDA issued another rejection for Atara Biotherapeutics’ allogeneic T‑cell therapy tabelecleucel (Ebvallo) for EBV‑positive post‑transplant lymphoproliferative disease, reversing prior agency...
WGS classifier finds HRD missed by standard tests: pan‑cancer study
A pan‑cancer study from Weill Cornell Medicine, Illumina and NewYork‑Presbyterian used whole‑genome sequencing (WGS) and an Isabl‑derived classifier to detect homologous recombination deficiency...
Bioprocess bets: Charles River buys PathoQuest and K.F.; Asimov licenses LV Edge to AGC
Charles River Laboratories exercised its option to acquire the remaining 79% of PathoQuest and agreed to buy assets of K.F. (Cambodia) to strengthen NGS‑based biologics QC and nonhuman primate...
Tahoe, Arc Institute and Biohub fund massive virtual‑cell dataset: 120M+ perturbations
Tahoe Therapeutics, the Arc Institute and Biohub committed multimillion‑dollar funding to generate a large, perturbation‑heavy single‑cell dataset to support virtual cell models. Tahoe will...
AbbVie buys PD‑1/VEGF bispecific: $650m upfront
AbbVie agreed to acquire ex‑China rights to RemeGen’s RC148, a PD‑1/VEGF‑targeted bispecific antibody, in a licensing deal that includes a $650 million upfront payment and up to $4.95 billion in...
Nvidia and Lilly put $1bn on the table: AI lab for drug discovery
Nvidia and Eli Lilly announced a five‑year, up‑to‑$1 billion co‑investment to create an AI drug‑discovery laboratory in San Francisco. Lilly will supply biological data and drug discovery...
Illumina unveils billion‑cell atlas... pharma signs on
Illumina launched a perturbation‑heavy single‑cell dataset it calls the Billion Cell Atlas and is offering the resource to pharmaceutical partners to fast‑track target validation and train AI...
Tahoe, Arc and Biohub build public virtual‑cell perturbation atlas
Tahoe Therapeutics, the Arc Institute and the Biohub committed multimillion‑dollar funding to build a public, perturbation‑heavy single‑cell dataset intended to accelerate virtual cell model...
Soley raises $200m Series C – advances stress‑sensing drug pipeline
Soley Therapeutics closed a $200 million Series C to move its stress‑sensing drug candidates into late‑stage development, with a focus on oncology, neurodegeneration and metabolic disease....
Tessera restructures after Regeneron tie‑up; advances AATD gene‑editing trial
Tessera Therapeutics announced a workforce reduction of about 35% as it shifts priorities around a collaboration with Regeneron that includes a $150 million investment to develop a gene‑editing...